首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

【24h】

Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL

机译：耗尽同种反应性T细胞（ATIR101）的供体淋巴细胞可提高T细胞贫乏单倍HSCT的无事件生存率（GRFS）和总体生存率：AML和ALL患者的2期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共7页
作者
Roy Denis-Claude; Lachance Silvy; Roy Jean; Walker Irwin; Maertens Johan; Delisle Jean-Sebastien; Foley Stephen Ronan; Lewalle Philippe; Olavarria Eduardo; Selleslag Dominik; Ruediger Manfred; Velthuis Jurjen; Gerez Lisya; Rovers Jeroen; Bonig Halvard; Mielke Stephan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL [J] . Roy Denis-Claude, Lachance Silvy, Roy Jean, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：耗尽同种反应性T细胞（ATIR101）的供体淋巴细胞可提高T细胞贫乏单倍HSCT的无事件生存率（GRFS）和总体生存率：AML和ALL患者的2期试验
2. Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies [J] . Roy Denis-Claude, Walker Irwin, Maertens Johan, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单剂量供体淋巴细胞的疗效和安全性耗尽的含有型T细胞（ATIR101）后T细胞耗尽的Haploidentical HSCT：两期II研究的合并分析
3. PHASE II CLINICAL TRIAL OF ALLODEPLETED T CELL IMMUNOTHERAPY (ATIR101) POST-TRANSPLANT RESULTS IN DECREASED TRANSPLANT-RELATED MORTALITY AND IMPROVED SURVIVAL IN ACUTE LEUKEMIA PATIENTS UNDERGOING T-DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION [J] . Roy D., Lachance S., Roy J., Cytotherapy . 2016,第6SSuppla期

机译：进行T缺失的半透明性干细胞移植的急性白血病患者移植后相关死亡率降低和存活率提高的同种异体T细胞免疫治疗（ATIR101）II期临床试验
4. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia [O] . Denis Claude Roy, Irwin Walker, Johan Maertens, -1

机译：T细胞贫血单倍HSCT后给予ATIR101可降低NRM并改善急性白血病的总体生存率
5. A Single Dose of Donor Lymphocytes Depleted of Alloreactive T Cells (ATIR101) after Haploidentical HSCT Is Well-Tolerated and Efficacious: Pooled Analysis of Two Phase II Studies [O] . Denis-Claude Roy, Irwin Walker, Johan Maertens, 2019

机译：单个剂量的供体淋巴细胞耗尽了聚体性T细胞（ATIR101）在寄和寄养的HSCT之后是良好的耐受性和有效的：汇总分析两期II研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号